Polskie Archiwum Medycyny Wewnętrznej
-
Pol. Arch. Med. Wewn. · Feb 2024
Multicenter StudyTreatment with Sofosbuvir/Velpatasvir of the most difficult to cure HCV-infected population.
Pangenotypic therapies for infections with hepatitis C virus (HCV), although universal and highly effective, entail a risk of treatment failure. ⋯ In a large population of SOF/VEL‑treated HCV‑infected patients, we showed relatively low effectiveness of the regimen in treatment‑experienced men with cirrhosis and obesity, infected with GT3. Triple therapy should be considered when initiating the treatment of HCV infections in this group, which, however, needs to be confirmed in further studies. Previous studies were conducted in less demanding populations, because they did not take into account sex and BMI, which significantly affect the treatment effectiveness.
-
Pol. Arch. Med. Wewn. · Feb 2024
Possible association of beta-blockers use with risk of intracranial aneurysm rupture.
Aneurysmal subarachnoid hemorrhage is a devastating type of stroke, associated with high mortality and morbidity. One of modifiable risk factors of aneurysm rupture is hypertension, however, it is still not clear whether any particular antihypertensive drugs play a significant role in the prevention of aneurysm rupture. ⋯ Aneurysm located in the anterior cerebral circulation might be less likely to rupture if patients receive β‑blockers or statins.
-
Pol. Arch. Med. Wewn. · Feb 2024
ReviewObesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists.
Worldwide prevalence of obesity is increasing dramatically, imposing a significant economic burden on our society. Treatment of obesity is challenging, potentially due to different disease phenotypes. Taking into consideration "obesities" rather than "obesity," and thus aiming to understand different pathophysiologic mechanisms of individual phenotypes, might help identify more tailored treatment strategies. ⋯ In the heart, GLP‑1RAs ameliorate cardiomyocyte survival and myocardial contractility, reduce cardiac hypertrophy, and are one of few drugs that can reduce epicardial fat thickness. In this review, we summarize recent evidence concerning the effects of GLP‑1RAs on obesity / dysmetabolism and on cardio- / cerebrovascular health. We further highlight the possible role of GLP‑1RAs in the treatment of obesity‑related CV diseases by describing the principal molecular mechanisms reported in the current literature.